Grant Sean 4
4 · Vera Therapeutics, Inc. · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
Vera Therapeutics (VERA) CFO Sean Grant Receives Stock Awards
What Happened
Sean Grant, Chief Financial Officer of Vera Therapeutics (VERA), received equity awards on February 4, 2026: 25,000 shares granted (reported as acquired at $0.00) and 50,000 derivative shares (reported as acquired at $0.00), for a reported transaction value of $0. These are grants/awards under the issuer's equity plan, not open-market purchases or sales.
Key Details
- Transaction date: February 4, 2026; Form 4 filed February 6, 2026 (timely within the usual two-business-day reporting window).
- Reported items: 25,000 shares (acquired at $0.00) and 50,000 derivative shares (acquired at $0.00). Total reported cash paid: $0.
- Shares owned after transaction: not specified in the data provided here—see the filed Form 4 for aggregate beneficial ownership amounts.
- Footnotes of note:
- F1: The derivative grant represents RSUs that vest one-fourth on each of Feb 20, 2027, 2028, 2029 and 2030, subject to continued service.
- F2: The reporting person’s holdings include 893 shares acquired under the 2021 ESPP on Sept 12, 2025.
- F3: Separately referenced stock option holdings vest 1/48th on March 4, 2026 and monthly thereafter (these are vesting schedule details for other option grants, not the Feb 4 RSU award).
- Transaction code: A = Award/Grant.
Context
These entries are compensation awards (restricted shares and RSUs). RSUs are derivative securities that convert to common stock only as they vest per the schedule in F1; they are not immediate open-market purchases. Such grants are common executive compensation and should be interpreted as awarded compensation rather than a direct market endorsement or sale.
Insider Transaction Report
- Award
Class A Common Stock
[F1][F2]2026-02-04+25,000→ 119,130 total - Award
Stock Option (right to buy)
[F3]2026-02-04+50,000→ 50,000 totalExercise: $42.74Exp: 2036-02-03→ Class A Common Stock (50,000 underlying)
- 5,000(indirect: By Trust)
Class A Common Stock
Footnotes (3)
- [F1]Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
- [F2]Includes 893 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on September 12, 2025.
- [F3]1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.